Asset Details
Do you wish to reserve the book?
Disease Modifying Effects of the Spider Toxin Parawixin2 in the Experimental Epilepsy Model
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Disease Modifying Effects of the Spider Toxin Parawixin2 in the Experimental Epilepsy Model
Do you wish to request the book?
Disease Modifying Effects of the Spider Toxin Parawixin2 in the Experimental Epilepsy Model
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Disease Modifying Effects of the Spider Toxin Parawixin2 in the Experimental Epilepsy Model
2017
Overview
(1) Background: Temporal lobe epilepsy (TLE) is the most common type of epilepsy in adults. It is also the one with the highest percentage of drug-resistance to the current available anti-epileptic drugs (AED). Additionaly, most antiepileptic drugs are only able to control seizures in epileptogenesis, but do not decrease the hippocampal neurodegenerative process. TLE patients have a reduced population of interneuronal cells, which express Parvalbumin (PV) proteins. This reduction is directly linked to seizure frequency and severity in the chronic period of epilepsy. There is therefore a need to seek new therapies with a disease-modifying profile, and with efficient antiepileptic and neuroprotective properties. Parawixin2, a compound isolated from the venom of the spider Parawixia bistriata, has been shown to inhibit GABA transporters (GAT) and to have acute anticonvulsant effects in rats. (2) Methods: In this work, we studied the effects of Parawixin2 and Tiagabine (an FDA- approved GAT inhibitor), and compared these effects in a TLE model. Rats were subjected to lithium-pilocarpine TLE model and the main features were evaluated over a chronic period including: (a) spontaneous recurrent seizures (SRS), (b) neuronal loss, and (c) PV cell density in different regions of the hippocampus (CA1, CA3, DG and Hilus). (3) Results: Parawixin2 treatment reduced SRS frequency whereas Tiagabine did not. We also found a significant reduction in neuronal loss in CA3 and in the hilus regions of the hippocampus, in animals treated with Parawixin2. Noteworthy, Parawixin2 significantly reversed PV cell loss observed particularly in DG layers. (4) Conclusions: Parawixin2 exerts a promising neuroprotective and anti-epileptic effect and has potential as a novel agent in drug design.
Publisher
MDPI AG,MDPI
Subject
/ Anticonvulsants - pharmacology
/ Anticonvulsants - therapeutic use
/ Epilepsy
/ Epilepsy, Temporal Lobe - chemically induced
/ Epilepsy, Temporal Lobe - drug therapy
/ Lithium
/ Male
/ Neuroprotective Agents - pharmacology
/ Neuroprotective Agents - therapeutic use
/ Neurotransmitter Uptake Inhibitors - pharmacology
/ Neurotransmitter Uptake Inhibitors - therapeutic use
/ Nipecotic Acids - pharmacology
/ Nipecotic Acids - therapeutic use
/ Seizures
/ Spider Venoms - pharmacology
/ Spider Venoms - therapeutic use
/ Spiders
/ Toxins
/ Urea - analogs & derivatives
/ Venom
